Browse the evidence

SGLT2 inhibitors reduce the risk of hospitalization for heart failure and all-cause mortality in patients with type 2 diabetes compared to DPP-4 inhibitors.

If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors (like empagliflozin). They are proven to lower the risk of heart failure hospitalization and death more effectively than DPP-4 inhibitors, offering significant cardiovascular protection beyond just blood sugar control.

Maternal obesity during the first trimester of pregnancy increases the risk of congenital heart defects and cardiovascular issues in offspring, mediated in part by maternal pregestational diabetes.

For women planning pregnancy, managing weight and blood sugar before conception is critical to protecting the child's long-term heart health. This is a preventative measure that starts before pregnancy.

Lasting remission of type 2 diabetes is not feasible in real-world settings due to the progressive nature of the disease, lack of consensus on definitions, and high rates of weight regain and treatment discontinuation.

Do not expect type 2 diabetes to be 'cured' or stay in remission without ongoing effort. Biological mechanisms will push your body to regain weight and increase hunger. Focus on sustainable management rather than a one-time fix, and maintain regular monitoring of cardiovascular and microvascular health even if your glucose levels are normal.

GLP-1 agonists and bariatric surgery can achieve high rates of remission, but these are not true remission as they require ongoing treatment, and long-term sustainability is low without continuous intervention.

GLP-1 agonists and surgery are effective for achieving remission, but they are not cures. You will likely need to continue treatment or accept the risks of surgery. Discuss with your doctor whether the benefits of these interventions outweigh the need for ongoing management.

Among adults aged 50 and older with newly diagnosed type 2 diabetes, the prevalence of undiagnosed (silent) hypertension reaches 50%, significantly higher than in younger diabetic cohorts.

If you are over 50 and have just been diagnosed with type 2 diabetes, you have a 1 in 2 chance of having high blood pressure that you don't know about. Because you likely have no symptoms, you must get your blood pressure checked immediately at diagnosis to prevent long-term heart and kidney damage.

In older adults (≥50 years) with newly diagnosed type 2 diabetes, mean systolic blood pressure often remains below the clinical hypertension threshold (140 mmHg) despite a high prevalence of silent hypertension, indicating subclinical vascular changes.

If you are over 50 with type 2 diabetes, do not assume your blood pressure is safe just because it is under 140 mmHg. Your blood vessels may already be stiffening, and your risk for heart disease is high even without a formal hypertension diagnosis. Monitor your BP closely and manage other risk factors like cholesterol and weight.

Age, BMI, HbA1c, family history of hypertension, and waist circumference are independent predictors of silent hypertension in newly diagnosed type 2 diabetes patients.

Your risk of having undiagnosed high blood pressure when you get diabetes depends on your age, weight, blood sugar control, family history, and waist size. If you have these risk factors, you are more likely to have silent hypertension and should be screened aggressively.

SGLT2 inhibitors provide significant cardiovascular and renal protection in type 2 diabetes patients through mechanisms independent of glycemic control, including metabolic reprogramming and fuel switching.

If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors. They protect your heart and kidneys through mechanisms beyond just lowering blood sugar, such as helping your body use different fuels. This can significantly reduce your risk of serious complications.

In patients with type 2 diabetes, the magnitude of weight loss achieved through semaglutide treatment (ranging from no loss to >10% loss) does not correlate with the risk of major adverse cardiovascular events (MACE), indicating that the drug's cardioprotective effects are independent of weight reduction.

If you are taking semaglutide for type 2 diabetes and cardiovascular risk, do not stop the medication if you are not losing as much weight as expected. The drug provides cardiovascular protection through direct effects on your blood vessels and heart, independent of how much weight you lose. Focus on the long-term heart health benefits rather than the number on the scale.

Postprandial glucose metabolism parameters derived from an Oral Glucose Tolerance Test (OGTT) do not predict anthropometric changes (weight, fat mass, or fat-free mass) following an 8-week low-calorie formula diet in adults with obesity.

If you are on a strict, low-calorie diet for 8 weeks, your body's specific glucose and insulin response to a sugar test (OGTT) will not help predict how much weight you will lose. The study found that baseline fat-free mass and sex were much better predictors of weight loss than metabolic phenotyping. Focus on adhering to the caloric deficit rather than seeking metabolic tests to guide short-term weight loss.

Menstrual cycle phase (follicular vs. luteal) and oral contraceptive use (active vs. placebo) do not significantly influence substrate oxidation (carbohydrate and fat ratios) at rest or during moderate-intensity continuous exercise.

You do not need to adjust your carbohydrate or fat intake based on where you are in your menstrual cycle or whether you are on birth control. The science shows that fuel oxidation remains consistent across phases. Focus on consistent nutrition and training intensity rather than trying to 'hack' your cycle for metabolic changes.

The central nervous system (CNS) acts as a fundamental regulator of glucose homeostasis by establishing a biologically defended level of glycemia (BDLG), and dysfunction in CNS control mechanisms contributes to the pathogenesis of type 2 diabetes (T2D) independently of pancreatic beta cell failure.

Current diabetes treatments often fail to achieve long-term remission because they only address insulin levels, ignoring the brain's role in setting a 'defended' high blood sugar level. Effective management may require strategies that address central nervous system regulation of glucose, not just pancreatic insulin output.

Higher central adiposity (measured by waist-to-hip ratio) causally increases the risk of kidney stone disease, mediated in part by elevated serum calcium concentrations.

Maintaining a healthy waist circumference is more critical for preventing kidney stones than general weight loss alone. Central fat raises serum calcium, which increases stone risk. Focus on reducing visceral fat through lifestyle changes to lower this specific biochemical risk.

Elevated GDF15 plasma levels are not a causal factor in cardiometabolic diseases such as obesity, type 2 diabetes, or cardiovascular disease, but rather serve as a biomarker of metabolic stress.

Do not rely on GDF15 levels to predict or treat obesity directly. While high GDF15 is a strong warning sign for heart disease and mortality, increasing it artificially (as done in animal studies) does not appear to cause weight loss in humans. Focus on established metabolic health markers instead.

Higher Body Mass Index (BMI) causally increases GDF15 plasma levels, identifying BMI as a driver of GDF15 elevation rather than the reverse.

High GDF15 is a consequence of higher body weight, not the cause. Managing BMI is the primary lever; GDF15 levels will naturally decrease as metabolic stress is reduced.

Obeticholic acid (25 mg/day) improves liver fibrosis in patients with MASH and stage 2-3 fibrosis, but does not significantly resolve MASH activity compared to placebo.

Obeticholic acid (25 mg daily) can significantly improve liver scarring (fibrosis) in patients with advanced MASH, but it does not reliably eliminate the inflammation (MASH) itself. The main barrier is itching (pruritus). This treatment is for specific high-risk patients, not general MASLD.

Pioglitazone (PPAR-gamma agonist) resolves MASH and reduces fibrosis stage, but its use is limited by adverse effects including fluid retention, weight gain, and osteopenia.

Pioglitazone can resolve MASH and reduce liver scarring, but it causes weight gain and fluid retention, which can worsen heart failure risk. It is generally limited by these side effects, particularly in older women due to fracture risk.

GIP receptor antagonism, specifically via the peptide GIP(3-30)NH2, increases GIP receptor surface expression and prevents internalization, thereby resensitizing the receptor for subsequent activation by endogenous or exogenous agonists.

Blocking the GIP receptor with specific antagonists like GIP(3-30)NH2 doesn't just turn off the signal; it keeps the receptors on the cell surface ready to receive signals. This resensitization may help overcome the impaired GIP response often seen in type 2 diabetes and obesity, potentially enhancing the effects of other treatments like GLP-1 agonists.

Higher body mass index (BMI) is associated with increased striatal dopamine tone in humans, as indicated by the differential displacement of low-affinity PET tracers ([11C]raclopride) compared to high-affinity tracers ([18F]fallypride).

This research suggests that higher body weight is linked to higher baseline (tonic) dopamine levels in the brain's reward centers, which may blunt the response to specific rewards. While this paper does not offer a direct intervention, it implies that weight loss might normalize dopamine tone, potentially improving reward sensitivity. However, the causal direction (does weight cause high dopamine or vice versa?) remains unproven in this cross-sectional study.

Exogenous testosterone administration (200 mg/week) does not alter whole-body energy expenditure, substrate oxidation, or skeletal muscle metabolic gene expression during a severe energy deficit in healthy men.

If you are a healthy man in a calorie deficit and exercising heavily, taking testosterone will not change how your body burns fat or carbs compared to not taking it. It helps preserve muscle mass, but it does not boost your metabolism or fat loss. Focus on your exercise volume and calorie intake for metabolic adaptations.

In individuals with type 2 diabetes who carry the haptoglobin (Hp) 2-2 phenotype, maintaining an HbA1c level below 6.5% does NOT significantly reduce the risk of coronary artery disease compared to levels of 7.0-7.9%.

If you have type 2 diabetes and have the haptoglobin 2-2 genetic variant, aiming for an HbA1c below 6.5% may not provide additional protection against heart disease compared to levels of 7.0-7.9%. This suggests that overly aggressive glycemic control might not be necessary or beneficial for cardiovascular health in this specific group.

Switching from Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in women with HIV results in significant weight loss, indicating TDF has weight-suppressive effects.

If you are a woman with HIV and are gaining weight on a TAF-based regimen, ask your doctor about switching to TDF. Studies show this switch can lead to significant weight loss (approx. 1.6 kg) in women, likely because TDF suppresses weight gain compared to TAF.

Classifying individuals by a 'leptin phenotype' (relatively high or low leptin for a given body fat percentage) does not predict differential energy expenditure, metabolic adaptation, or susceptibility to weight change in response to caloric restriction or overfeeding.

Do not rely on fasting leptin levels to predict your weight loss success or failure. Whether your leptin is 'high' or 'low' for your body fat percentage does not appear to change how your body responds to dieting or overeating in terms of energy expenditure or weight change. Focus on sustainable caloric deficits and activity rather than hormonal profiling for prediction.

A 2-week exposure to either a low-carbohydrate (LC) or low-fat (LF) diet does not significantly alter sweet or salty taste detection thresholds or preferences compared to each other.

Switching to a low-carb or low-fat diet for just two weeks will not change your taste buds or your cravings for sweet and salty foods. If you are expecting your food preferences to shift quickly as a result of the diet itself, this short timeframe is likely too short to observe such changes.